NYSEAMERICAN:BTX - BioTime, Inc.
$1.25
 $0.05
+4.17%
4:00PM EDT
2019-04-18
BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company's clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery.The Company's lead facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus (HIV). OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial (RPE) cells that are derived from pluripotent stem cells. RPE cells form the back lining of the retina, and support the function of photoreceptors (rods and cones). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BTX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 39   203. 85   241. 91  
42 stocks rank:  3. 97 K 1. 44 K 1. 05 K
# analyst opinions:  6. 00   14. 51   13. 97  
mean recommendation:  1. 70   2. 09   2. 01  

quick ratio:  5. 06   5. 27   1. 81  
current ratio:  5. 34   5. 62   2. 25  

target price low:  3. 00   84. 80   115. 21  
target price avg:  1. 59   111. 51   137. 51  
target price high:  2. 23   135. 81   157. 84  
1-yr high:  2. 79   114. 23   138. 78  
last close:  1. 25   87. 66   116. 69  
50-day avg:  1. 32   95. 54   123. 44  
200-day avg:  1. 75   94. 25   121. 11  
1-yr low:  0. 86   72. 78   98. 34  
volume:  539. 68 K 4. 11 M 8. 07 M
50-day avg volume:  877. 87 K 2. 76 M 5. 02 M
200-day avg volume:  711. 33 K 2. 92 M 4. 59 M

1-day return:  4. 17 % -0. 41 % 0. 07 %
this week return:  -3. 10 % -5. 74 % -4. 11 %
12-wk return:  32. 98 % 1. 61 % -0. 05 %
52-wk return:  -48. 05 % 3. 12 % 8. 78 %

enterprise value (EV):  149. 16 M 48. 94 B 114. 64 B
market cap:  186. 70 M 43. 07 B 104. 73 B
EBITDA:  -37. 72 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -3. 95   4. 22   12. 73  
enterprise/revenue (EV/R):  29. 90   63. 17   12. 84  
total revenue:  4. 99 M 10. 62 B 38. 47 B
total debt:  2. 27 M 12. 24 B 16. 73 B
debt/equity:  2. 46   46. 71   89. 62  
net income (common):  -45. 99 M 2. 20 B 4. 20 B

shares outstanding:  149. 36 M 571. 70 M 1. 24 B
shares:  107. 43 M 571. 81 M 1. 23 B
shares short:  10. 52 M 10. 17 M 13. 00 M
shares short prior month:  9. 91 M 9. 54 M 17. 33 M
short ratio:  9. 37   5. 41   3. 28  
total cash/share:  0. 21   11. 14   9. 33  
total cash:  30. 74 M 6. 71 B 7. 15 B
free cash flow:  -21. 53 M 3. 58 B 2. 96 B
operating cash flow:  -30. 88 M 4. 15 B 4. 30 B

book value:  0. 74   12. 78   26. 92  
price/book:  1. 69   3. 06   -1. 74  
operating margins:  -821. 87 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  93. 95 % 37. 08 % 55. 70 %

1-yr max volatility:  56. 18 % --- ---
1-yr mean volatility:  -0. 11 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 36   2. 40   4. 10  
forward EPS:  -0. 19   3. 97   7. 13  
P/E:  -3. 45   13. 63   22. 72  
forward P/E:  -6. 58   -15. 95   13. 99  
PE/G:  0. 14   -1. 65   -1. 32  
growth:  -24. 10 % 127. 12 % 29. 61 %
earnings high:  -0. 05   1. 00   1. 66  
earnings avg:  -0. 06   0. 77   1. 53  
earnings low:  -0. 07   0. 50   1. 39  
revenue high:  1. 18 M 2. 68 B 10. 78 B
revenue avg:  910. 00 K 2. 59 B 10. 57 B
revenue low:  700. 00 K 2. 49 B 10. 36 B
return on assets:  -18. 64 % -2. 75 % 4. 55 %
return on equity:  -36. 48 % -18. 45 % 5. 46 %
revenue growth:  -24. 10 % 92. 86 % 18. 96 %
revenue/share:  0. 04   13. 29   55. 46  

beta (1yr vs S&P500):  1. 40   1. 25   0. 93  
sharpe (1yr):  -0. 32   0. 37   0. 70  

held % insiders:  5. 79 % 6. 39 % 3. 38 %
held % institutions:  40. 92 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : BTX
.    + 0.756 =         0.756 :: INITIAL WEIGHT
.   + 38.746 =        39.502 :: spline projection addition
.    x 1.431 =        56.544 :: industry recommendation factor
.    x 2.565 =       145.042 :: symbol recommendation factor
.    x 1.473 =       213.698 :: EV/R factor
.    x 0.998 =         213.3 :: return on assets factor
.    x 0.996 =       212.522 :: return on equity factor
.    x 0.998 =        212.01 :: revenue growth factor
.    x 2.949 =       625.201 :: current ratio factor
.    x 1.116 =       697.979 :: quick ratio factor
.    x 1.052 =       734.281 :: short ratio factor
.    x 2.017 =      1480.998 :: price-to-book factor
.    x 1.026 =      1519.416 :: debt-to-equity factor
.    x 2.117 =      3215.871 :: P/E weight
.    x 1.625 =        5227.0 :: PE/G factor
.    x 1.539 =      8043.954 :: beta factor
.    x 0.319 =      2567.729 :: sharpe factor
.    x 2.358 =      6053.923 :: target low factor
.    x 1.174 =      7108.765 :: target mean factor
.    x 1.088 =      7737.614 :: target high factor
.     x 1.31 =     10135.407 :: industry 2-weeks return factor
.     x 0.89 =      9021.892 :: "drift" penalty 4 days ago
.    x 0.955 =      8615.373 :: overall "drift" factor
.    x 0.438 =      3775.276 :: largest single-day jump factor
.    x 0.063 =       236.992 :: low price factor
.      x 1.0 =       236.953 :: factor hist industry gain for week 16
.   cubeRoot =         6.188 :: reduced to standardize
.   - 25.274 =         0.392 :: add/subtract for performance
.                      0.392 :: FINAL WEIGHT for NYSEAMERICAN:BTX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org